Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Summary

This phase I trial is studying the side effects and best dose of vorinostat when given together with bortezomib in treating patients with relapsed or refractory multiple myeloma. Vorinostat and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving vorinostat together with bortezomib may kill more cancer cells

Timeline

Start

2005-11

Primary completion

2008-02

Completion

—

Drugs

Indications